• Oscar Arrieta, Carlos Campillo, Rubén Burgos, Miguel Ángel Celis, Manuel De la Llata, Judith Domínguez, José Halabe, Sergio Islas, Luis Jasso, Alberto Lifshitz, Mucio Moreno, Ricardo Plancarte, Alejandro Reyes-Sánchez, Guillermo J Ruiz-Argüelles, Antonio Soda, Emma Verástegui, and Julio Sotelo.
• Academia Nacional de Medicina, Comité de Ética y Transparencia en la Relación Médico-Industria, Ciudad de México, México.
• Gac Med Mex. 2019 Jan 1; 155 (3): 319-321.

AbstractClinical research is the most important tool for the identification of diagnostic and therapeutic strategies that derive in higher efficacy and safety. Despite its significance, successful implementation of clinical research faces numerous difficulties, with one the most relevant being limited availability of resources for the performance of independent clinical trials. Generally, the pharmaceutical industry absorbs the costs associated with most clinical trials; however, this can generate dissociation between subjects of interest and health priorities when economic interest is the main driver of these protocols. In addition to the relevant role played by the pharmaceutical industry, it is important that government agencies favor adequate conditions, both in economic and regulatory aspects, for the implementation of independent clinical research that addresses subjects of medical and therapeutic interest, even if it does not generate corporate economic benefits.Copyright: © 2019 SecretarÍa de Salud.

14 keywords...

hide…